Related Experiment Video
Updated: May 10, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
TLK1 as a therapeutic target in TMZ resistant glioblastoma using small molecule inhibitor
Bhanu Priya1, Sivapriya Kirubakaran2
1Department of Biological Sciences and Engineering, Indian Institute of Technology, Palaj Campus, Gandhinagar, Gujarat, 382355, India.
Abstract:
The acquired resistance to existing therapies poses a grave concern in achieving successful therapeutic outcomes. Temozolomide (TMZ), a widely used alkylating chemotherapeutic in Glioblastoma therapy, often encounters resistance, necessitating the investigation of the underlying mechanisms of TMZ-acquired resistance. To study TMZ resistance, a cell-based model system was generated by intermittently exposing glioblastoma cells to increasing concentrations and time of TMZ over six months. The survival response of cells at higher concentrations confirmed TMZ-resistant cells, which exhibited a phenotypic shift toward a mesenchymal-like state, with decreased epithelial traits, indicating mesenchymal-epithelial transition (MET). This transition likely facilitates the stabilization and clonal growth of TMZ-resistant cells. Subsequent analysis revealed elevated expression of TLK1, a DNA repair protein, thus reinforcing its potential involvement in mechanisms associated with acquired resistance. To explore the therapeutic aspect of TLK1 inhibition, we utilized an in-house developed TLK1 inhibitor, J54. The inhibition of TLK1 in TMZ-resistant cells enhanced cytotoxicity, indicating TLK1 as a potential target to combat TMZ resistance. Moreover, TLK1 inhibition reduced cell migration and invasion, implying its role in promoting metastasis. In conclusion, our study sheds light on the role of TLK1 in the context of TMZ resistance, highlighting its potential as a valuable target for therapeutic intervention.
Insights
Acquired resistance to temozolomide (TMZ) in glioblastoma involves a mesenchymal-epithelial transition (MET) and elevated TLK1 expression. Inhibiting TLK1 in resistant cells enhanced cytotoxicity and reduced metastasis, identifying TLK1 as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Acquired resistance to chemotherapy, specifically temozolomide (TMZ), is a major challenge in glioblastoma (GBM) treatment.
- Understanding the mechanisms behind TMZ resistance is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To investigate the mechanisms underlying acquired TMZ resistance in glioblastoma cells.
- To evaluate the potential of targeting TLK1 as a therapeutic strategy to overcome TMZ resistance.
Main Methods:
- A cell-based model of TMZ resistance was established by prolonged exposure of glioblastoma cells to increasing TMZ concentrations.
- Phenotypic changes, including epithelial-mesenchymal transition (EMT), were analyzed.
- Expression levels of the DNA repair protein TLK1 were assessed.
- The efficacy of a TLK1 inhibitor (J54) on TMZ-resistant cells was evaluated for cytotoxicity, migration, and invasion.
Main Results:
- TMZ-resistant glioblastoma cells exhibited a mesenchymal-like phenotype, indicative of mesenchymal-epithelial transition (MET).
- Elevated expression of TLK1, a DNA repair protein, was observed in TMZ-resistant cells.
- Inhibition of TLK1 using J54 significantly enhanced the cytotoxicity of TMZ-resistant cells.
- TLK1 inhibition also reduced the migration and invasion capabilities of these resistant cells.
Conclusions:
- Mesenchymal-epithelial transition (MET) and increased TLK1 expression are associated with acquired temozolomide resistance in glioblastoma.
- TLK1 inhibition represents a promising therapeutic approach to overcome TMZ resistance and potentially reduce glioblastoma metastasis.
More Related Videos
09:24Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
Published on: June 9, 2016
09:26Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011
